Physician profile
Larry A Evans
NPI 1083682439
$674.90
in general payments reported to CMS, 2019-2025
12 companies · $494 in 2025
The $494 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20.54 · 2024: $160 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $124.24 | 2024-2025 | |
| Janssen Biotech, INC. | $111.38 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $105.02 | 2024-2025 | |
| Abbvie INC. | $94.25 | 2024 | |
| Ucb, INC. | $67.59 | 2025 | Bimzelx |
| Leo Pharma INC. | $30.06 | 2025 | Adbry |
| Incyte Corporation | $28.48 | 2025 | Opzelura |
| Genzyme Corporation | $26.16 | 2025 | |
| Amgen INC. | $24.76 | 2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $22.84 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $20.54 | 2023 | Ycanth |
| Pfizer INC. | $19.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.